- Home
- FMST vs SYBX Comparison
FMST vs SYBX Comparison
Compare FMST & SYBX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FMST
- SYBX
- Stock Information
- Founded
- FMST 2005
- SYBX N/A
- Country
- FMST Canada
- SYBX United States
- Employees
- FMST N/A
- SYBX N/A
- Industry
- FMST Other Metals and Minerals
- SYBX Biotechnology: Pharmaceutical Preparations
- Sector
- FMST Basic Materials
- SYBX Health Care
- Exchange
- FMST Nasdaq
- SYBX Nasdaq
- Market Cap
- FMST 15.8M
- SYBX 16.7M
- IPO Year
- FMST N/A
- SYBX N/A
- Fundamental
- Price
- FMST $2.00
- SYBX $1.39
- Analyst Decision
- FMST
- SYBX Buy
- Analyst Count
- FMST 0
- SYBX 4
- Target Price
- FMST N/A
- SYBX $15.50
- AVG Volume (30 Days)
- FMST 13.3K
- SYBX 11.4K
- Earning Date
- FMST 01-01-0001
- SYBX 11-12-2024
- Dividend Yield
- FMST N/A
- SYBX N/A
- EPS Growth
- FMST N/A
- SYBX N/A
- EPS
- FMST N/A
- SYBX N/A
- Revenue
- FMST N/A
- SYBX $2,777,000.00
- Revenue This Year
- FMST N/A
- SYBX N/A
- Revenue Next Year
- FMST N/A
- SYBX N/A
- P/E Ratio
- FMST N/A
- SYBX N/A
- Revenue Growth
- FMST N/A
- SYBX 292.23
- 52 Week Low
- FMST $1.94
- SYBX $1.22
- 52 Week High
- FMST $4.25
- SYBX $5.12
- Technical
- Relative Strength Index (RSI)
- FMST 33.44
- SYBX 43.69
- Support Level
- FMST $1.94
- SYBX $1.37
- Resistance Level
- FMST $2.19
- SYBX $1.58
- Average True Range (ATR)
- FMST 0.19
- SYBX 0.08
- MACD
- FMST -0.01
- SYBX -0.00
- Stochastic Oscillator
- FMST 8.43
- SYBX 7.14
About FMST Foremost Lithium Resource & Technology Ltd. Common stock
Foremost Clean Energy Ltd is an emerging North American uranium and lithium exploration company. Its uranium portfolio consists of projects at different stages of exploration from grassroots, to those with significant historical exploration and drill-ready targets. It also maintains a secondary portfolio of lithium projects at different stages of development spanning 50,000-plus acres across Manitoba and Quebec.
About SYBX Synlogic Inc.
Synlogic Inc is a biopharmaceutical company focuses on rare metabolic disorders, with a lead program in phenylketonuria (PKU) and homocystinuria (HCU). The company's pipeline includes therapeutics for enteric hyperoxaluria, gout, and cystinuria. Using a proprietary approach, the company engineer GI-restricted, oral medicines from well-characterized probiotics. These drug candidates target specific biological pathways, leveraging Escherichia coli Nissle 1917 for consistency and safety. Engineered to be non-colonizing and reversible, the company offer oral administration, simplifying shipping and storage. The company operates in one segment-discovery and development of Synthetic Biotics-pioneering transformative treatments for serious diseases.